Botox
(OnabotulinumtoxinA)ApprovedSmall molecule
OnabotulinumtoxinA is used to reduce the appearance of wrinkles and fine lines by relaxing facial muscles, and it's also used to treat various medical conditions like chronic migraines, muscle spasms, and excessive sweating.[2] Botox is currently approved and in use across 109 indications[4].[1]
Botox is one of 1387 small molecule programs targeting Plantar Fasciitis. It is currently in Approved.
109
Indications
86
Total Trials
9
Active Trials
1,386
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 106 indications
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Meglitinides
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Thiazolidinediones
SanofiPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine11 trials
Show 8 more trials
Efficacy of OnabotulinumtoxinA in Migraine
Completed·IIRCCS National Neurological Institute "C. Mondino" Foundation·Phase 2·NCT04578782·32 enrolled
BOTOX® vs. XEOMIN® for Chronic Migraine
Recruiting·—·Phase 3·NCT05598723·128 enrolled
Calcitonin Gene-related Peptide Levels in Chronic Migraine
Completed·—·Phase 4·NCT01071096·20 enrolled
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
Completed·—·Phase 4·NCT02037425·44 enrolled
OnabotulinumtoxinA9 trials
Show 6 more trials
Urinary incontinence8 trials
Show 5 more trials
Safety and Efficacy6 trials
Spasticity4 trials
Show 1 more trial
Early Use of Botulinum Toxin in Spasticity Post Stroke.
Completed·—·Phase 2·NCT01882556·120 enrolled
33 more indications
Moderate to Severe Glabellar Lines4 trials
Overactive Bladder3 trials
Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial
Unknown status·—·Phase 4·NCT05157295·100 enrolled
Botulinum Toxin3 trials
Headache3 trials
Osteoarthritis2 trials
Glabellar Frown Lines2 trials
Botox2 trials
Bruxism2 trials
Patient Satisfaction2 trials
Glabellar Lines2 trials
Adverse Effect1 trial
Premature Ejaculation1 trial
Granuloma1 trial
Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas
Withdrawn·—·Phase 2·NCT01678053
Major Depressive Disorder1 trial
Stroke1 trial
Satisfaction1 trial
Hyperhidrosis1 trial
Cervical Dystonia1 trial
Cerebral Palsy1 trial
Treatment1 trial
Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED
Unknown status·—·Phase 2/3·NCT04172558·124 enrolled
Facial Wrinkles1 trial
Chronic Pelvic Pain1 trial
Facial Aging1 trial
Regulatory
FDA Approval Timeline[5]
Dec 9, 1991
BOTOX COSMETIC
BLA BLA103000
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Botox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for OnabotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details